ライフサイエンスコーパス: dermatophyte

1 nterlaboratory agreement when tested against dermatophytes.

2 life-threatening fungal infection caused by dermatophytes.

3 ample, Eurotiomycetes, which includes common dermatophytes.

4 ing method has been standardized for testing dermatophytes.

5 o determine the antifungal susceptibility of dermatophytes.

6 nst various fungi species, such as molds and dermatophytes.

7 ool for antifungal susceptibility testing of dermatophytes.

8 does not specifically address the testing of dermatophytes.

9 and, Ohio, for testing the susceptibility of dermatophytes.

10 i does not explicitly address the testing of dermatophytes.

11 the NCCLS M38-A standard for the testing of dermatophytes.

12 usefulness for presumptive identification of dermatophytes.

13 y that discriminated T. tonsurans from other dermatophytes.

14 idation of the method with a large number of dermatophytes.

15 antifungal susceptibility testing method for dermatophytes.

16 ghest antifungal activity against all of the dermatophytes.

17 the susceptibility testing of ME1111 against dermatophytes according to M38-A2 methodology, which sti

18 to test the susceptibility of 47 isolates of dermatophytes against 8 antifungals.

19 ndula luisieri essential oils against yeast, dermatophyte and Aspergillus strains responsible for hum

20 an optimal medium for conidial formation by dermatophytes and (ii) validation of the method with a l

21 In studies of over 500 isolates of dermatophytes and common nondermatophyte molds, as well

22 Dermatophyte binding was inhibited completely by the add

23 quence, we questioned whether its binding to dermatophytes can induce tyrosine phosphorylation in den

24 Dermatophytes cause superficial and cutaneous fungal inf

25 c fungi that were morphologically similar to dermatophytes caused false-positive results.

26 the isolates for the majority of tested drug-dermatophyte combinations.

27 DiversiLab system for identification of the dermatophytes commonly encountered in a clinical mycolog

28 the DiversiLab system for identification of dermatophytes commonly isolated in a clinical laboratory

29 t the in vitro activities of TDT 067 against dermatophytes, compared with those of the Transfersome v

30 archived dermatophyte isolates and 71 fresh dermatophyte cultures were evaluated using both librarie

31 spectrometer (MS) for the identification of dermatophytes from clinical cultures was compared to tha

32 The dermatophyte fungus Trichophyton exhibits unique immunol

33 btilase homologue, Tri r 2, derived from the dermatophyte fungus Trichophyton rubrum, exhibits unique

34 Skin testing with an extract from the dermatophyte fungus Trichophyton tonsurans can result in

35 A new medium, Dermatophyte Identification Medium (DIM) (trade mark pen

36 Only 25 of 77 dermatophytic isolates caused dermatophyte identification medium (DIM) to turn purple

37 om clinical cultures was compared to that of dermatophyte identification using 28S rRNA gene sequenci

38 tive to traditional or molecular methods for dermatophyte identification, provided that the reference

39 A standardized reference method for dermatophyte in vitro susceptibility testing is lacking.

40 method for the presumptive identification of dermatophytes in the clinical mycology laboratory.

41 the introduction of this method for testing dermatophytes in the future version of the CLSI M38-A st

42 Initially, he worked with dermatophytes in Winnipeg, where he was influenced by Bu

43 arotitis, polymicrobial bacteremia, invasive dermatophyte infection and Clostridium difficile-associa

44 ndition is different from common superficial dermatophyte infection and has been reported in patients

45 pes zoster (IR, 1.11; 95% CI, 0.88-1.39), 57 dermatophyte infections (IR, 0.88; 0.67-1.14), and 52 or

46 , are unable to clear superficial Candida or Dermatophyte infections and suffer with chronic mucocuta

47 Mucocutaneous candidiasis and dermatophyte infections occur either in isolation or alo

48 Dermatophytes initiate dermatophytosis, but susceptibili

49 of seven antifungal agents tested against 25 dermatophyte isolates (5 blinded pairs of five dermatoph

50 One hundred well-characterized, archived dermatophyte isolates and 71 fresh dermatophyte cultures

51 study, the voriconazole susceptibilities of dermatophyte isolates obtained from a worldwide tinea ca

52 Forty-eight dermatophyte isolates, including Trichophyton rubrum (n

53 Dermatophytes of the genus Trichophyton cause infections

54 e fungal diseases caused by Candida species, dermatophytes, or Phialophora verrucosa.

55 ve identification of an unknown isolate as a dermatophyte required only the transfer of a portion of

56 rmatophyte isolates (5 blinded pairs of five dermatophyte species per site for a total of 300 tests),

57 tion of multiple genetic strains of a single dermatophyte species should not be unexpected in areas o

58 Initially, five dermatophyte species were tested for their ability to in

59 lemented library containing an additional 20 dermatophyte spectra (S-MBL).

60 by anthropophilic, geophilic, and zoophilic dermatophyte strains and (ii) the keratinocyte signaling

61 067 demonstrated potent activity against the dermatophyte strains tested, with an MIC range of 0.0000

62 mation along with the optimal conditions for dermatophyte susceptibility testing proposed by Norris e

63 ed with commercially marketed media, such as dermatophyte test medium (DTM).

64 The dermatophytes tested included Trichophyton rubrum, Trich

65 r a total of 300 tests), using the method of dermatophyte testing developed at the Center for Medical

66 has more potent antifungal activity against dermatophytes that cause nail infection than conventiona

67 mined the antifungal susceptibilities of 217 dermatophytes to fluconazole, griseofulvin, itraconazole

68 r determining antifungal susceptibilities of dermatophytes to terbinafine, ciclopirox, and voriconazo

69 s a nonpathogenic fungus which resembles the dermatophyte Trichophyton rubrum.

70 efine two distinct antigens derived from the dermatophyte Trichophyton that serve as targets for dive

71 howed soluble recombinant DC-HIL to bind the dermatophytes Trichophyton rubrum and Microsporum audoui

72 ound have been tested against the pathogenic dermatophytes Trichophyton rubrum and Trichophyton menta

73 matory responses induced by a representative dermatophyte, Trichophyton equinum.

74 cating that germination may be important for dermatophyte virulence and host immune activation.

75 Using T. equinum as a representative dermatophyte, we found that the mitogen-activated protei

76 voriconazole against 19 different species of dermatophytes were compared with those of terbinafine, i

77 conidial growth, representative isolates of dermatophytes were grown on different agars.

78 Seven antifungals with activity against dermatophytes were tested, including ciclopirox, flucona

79 ates, with the exception of 45 yeasts and 15 dermatophytes, were recovered from both storage temperat